Get the Stockscreener App
12.08
0.25%
-0.03
Pre-market:
11.51
-0.57
-4.72%
Bicara Therapeutics Inc stock is traded at $12.08, with a volume of 350.93K.
It is down -0.25% in the last 24 hours and down -31.32% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
See More
Previous Close:
$12.11
Open:
$12.19
24h Volume:
350.93K
Relative Volume:
0.87
Market Cap:
$657.34M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-5.88%
1M Performance:
-31.32%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$11.69
$12.48
1-Week Range:
$11.56
$13.96
52-Week Range:
$11.56
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-785-8308
Address
245 MAIN STREET, CAMBRIDGE
Compare BCAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
12.08 | 657.34M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
Barclays PLC Purchases Shares of 10,000 Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Initiates Corporate Presentation on Promising Corporate Strategy - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Head-To-Head Contrast: Bicara Therapeutics (NASDAQ:BCAX) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 4.1%Here's What Happened - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week LowHere's What Happened - MarketBeat
Head to Head Analysis: Immunome (NASDAQ:IMNM) vs. Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Geode Capital Management LLC Buys Shares of 48,639 Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Geode Capital Management LLC Takes $1.24 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Jane Street Group LLC Makes New $309,000 Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Third Rock-backed Maze Therapeutics reveals profit in US IPO filing - Reuters
Bicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year LowWhat's Next? - MarketBeat
Barclays PLC Takes $255,000 Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 2.9%What's Next? - MarketBeat
Biotech IPO Shares 2025 Climb In Trading Debuts After Deals Upsized - Browvopetshop
Bicara’s era? Merus, ALX also active in head and neck cancer - BioWorld Online
Most important biotech stories of 2024: IPOs, M&A deals and more layoffs - The Business Journals
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.00 Average PT from Analysts - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 5.9%What's Next? - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Rating of "Buy" by Analysts - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Trading 5.5% HigherStill a Buy? - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Down – Should You Sell? - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap DownTime to Sell? - MarketBeat
This cancer drug developer held the Bay State's largest IPO of 2024 - The Business Journals
Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year LowWhat's Next? - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 5.8%Time to Sell? - MarketBeat
The Manufacturers Life Insurance Company Takes $582,000 Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
763,943 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Wellington Management Group LLP - MarketBeat
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Point72 Asset Management L.P. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Now Covered by HC Wainwright - MarketBeat
Janus Henderson Group PLC Buys New Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
31,780 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Walleye Capital LLC - MarketBeat
2,273,792 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Fmr LLC - MarketBeat
HC Wainwright & Co. Initiates Coverage of Bicara Therapeutics (BCAX) with Buy Recommendation - MSN
Maven Securities LTD Buys Shares of 50,000 Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
35,000 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Acquired by Samsara BioCapital LLC - MarketBeat
RA Capital Management L.P. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Point72 DIFC Ltd Takes $1.42 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Baker BROS. Advisors LP Makes New $21.23 Million Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Braidwell LP Makes New $42.22 Million Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Vestal Point Capital LP Acquires Shares of 425,000 Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
First Turn Management LLC Takes $14.32 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
FY2024 EPS Estimates for BCAX Cut by Cantor Fitzgerald - Defense World
FY2024 EPS Estimates for BCAX Reduced by Cantor Fitzgerald - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 6.2%Here's Why - MarketBeat
Bicara Therapeutics Inc Stock (BCAX) Financials Data
There is no financial data for Bicara Therapeutics Inc (BCAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):